On February 1, 2024, Incannex Healthcare Inc., a clinical stage pharmaceutical development company, announced a significant milestone in the field of psychedelic-assisted therapies. The company's collaboration with Clarion Clinics has led to the Therapeutic Goods Administration (TGA) granting approval for Professor Suresh Sundram, co-founder and Head of Psychiatry at Clarion Clinics, to prescribe MDMA for Post-traumatic Stress Disorder (PTSD) and psilocybin for Treatment-resistant Depression (TRD) at their Melbourne clinic. This approval follows the TGA's down-scheduling of these substances, allowing their use in clinical service delivery. Clarion Clinics, located in Abbottsford, Melbourne, is now the first dedicated psychedelic-assisted therapy clinic in Australia, designed to provide an optimal environment for treatment. Incannex Healthcare is pursuing U.S. FDA approval for its drug therapies and holds 19 granted patents and 30 pending applications. The company is listed on NASDAQ under the ticker IXHL.

On February 1, 2024, Incannex Healthcare Inc., a clinical stage pharmaceutical development company, announced a significant milestone in the field of psychedelic-assisted therapies. The company's collaboration with Clarion Clinics has led to the Therapeutic Goods Administration (TGA) granting approval for Professor Suresh Sundram, co-founder and Head of Psychiatry at Clarion Clinics, to prescribe MDMA for Post-traumatic Stress Disorder (PTSD) and psilocybin for Treatment-resistant Depression (TRD) at their Melbourne clinic. This approval follows the TGA's down-scheduling of these substances, allowing their use in clinical service delivery. Clarion Clinics, located in Abbottsford, Melbourne, is now the first dedicated psychedelic-assisted therapy clinic in Australia, designed to provide an optimal environment for treatment. Incannex Healthcare is pursuing U.S. FDA approval for its drug therapies and holds 19 granted patents and 30 pending applications. The company is listed on NASDAQ under the ticker IXHL.